Methadone is extensively used in the maintenance treatment of addicts and in the management of severe pain. In order to use methadone with HIV protease inhibitors correctly, it is important to evaluate and quantify interactions between the protease inhibitors and methadone.

Patients receive their usual daily dose of methadone followed with ritonavir and saquinavir, respectively, twice a day. Patients are evaluated on Day 4 for safety and tolerance, and their ritonavir dose is increased. On Day 8 patients are evaluated for a steady-state level of methadone. After 2 weeks of the protease inhibitor therapy, they return for methadone pharmacokinetic sampling at Day 15 over 24 hours. Both protease inhibitors and methadone are administered on Day 15 on an inpatient basis. On Day 30, patients are assessed for safety and tolerance.

Inclusion Criteria

You may be eligible for this study if you:

• Are HIV-positive and have an HIV RNA count below 100,000 copies/ml within 30 days prior to study entry.
• Are taking methadone.
• Are at least 18 years old.
• Are within 40% of your ideal body weight and weigh at least 99 lbs.

Exclusion Criteria

You will not be eligible for this study if you:

• Are allergic to or are unable to take RTV or SQV.
• Have a history of treatment failure with indinavir, RTV, or SQV.
• Have a history of certain illnesses that might prevent you from completing the study.
• Have severe diarrhea or other stomach problems.
• Have taken any PI within 4 weeks prior to study entry.
• Would be unable to complete the study due to alcohol or drug abuse.
• Are co-enrolled in other protocols that have you taking medications that are prohibited in this study.
• Are taking PIs other than RTV or SQV.
• Are receiving certain therapies or are taking certain medications, including experimental drugs.
• Have an active opportunistic (AIDS-related) infection or disease that requires medication within 14 days prior to study entry.
• Are pregnant or breast-feeding.